| II-36 Rubin Lubomirov Population pharmacokinetic-based, two-stage approach to assess the impact of genetic variants on lurbinectedin exposure in patients with advanced cancer Wednesday 15:10-16:40 |
| II-36 Rubin Lubomirov Population pharmacokinetic-based, two-stage approach to assess the impact of genetic variants on lurbinectedin exposure in patients with advanced cancer Wednesday 15:10-16:40 |